Development and evaluation of a patient-reported outcome measure specific for Gaucher disease with or without neurological symptoms in Japan

被引:1
|
作者
Narita, Aya [1 ]
Koto, Yuta [2 ]
Noto, Shinichi [3 ]
Okada, Masafumi [4 ]
Ono, Midori [5 ]
Baba, Terumi [5 ]
Sagara, Rieko [5 ]
Sakai, Norio [6 ]
机构
[1] Tottori Univ, Div Child Neurol, Inst Neurol Sci, Fac Med, Yonago, Japan
[2] Osaka Aoyama Univ, Fac Hlth Sci, Sch Nursing, Osaka, Japan
[3] Niigata Univ Hlth & Welf, Dept Rehabil, Niigata, Japan
[4] IQVIA Solut Japan KK, Real World Evidence Solut & HEOR, Tokyo, Japan
[5] Takeda Pharmaceut Co Ltd, Japan Med Off, Tokyo, Japan
[6] Osaka Univ, Grad Sch Med, Div Hlth Sci, Child Healthcare & Genet Sci Lab, 1-7 Yamadaoka, Suita, Osaka 5650871, Japan
关键词
Gaucher disease; Japan; Patient reported outcome measures; Quality of life; Burden of disease; Neuronopathic Gaucher disease; Reliability; Validity;
D O I
10.1186/s13023-023-02996-9
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background Patients with Gaucher disease (GD), a rare lysosomal storage disorder, have reduced health-related quality of life (HRQOL). A patient-reported outcome measure (PROM) for HRQOL developed for type 1 GD (GD1) is not appropriate for patients with neuronopathic GD (nGD) types 2 (GD2) and 3 (GD3). In this study, we developed a new PROM for use in all GD types. We previously reported the qualitative analysis of interviews with Japanese patients with nGD, which was used to create nGD-specific PROM items. Here we evaluated the full PROM combining the type 1 questionnaire with the new nGD-specific items.Methods Patients with confirmed GD were recruited (Association of Gaucher Disease Patients in Japan or leading doctors) for pre-testing (May 2021) or the main survey (October-December 2021). The PROM had three parts: Parts 1 and 2 were translated into Japanese from the pre-existing GD1 PROM, whereas Part 3 was newly developed. Patients (or their caregivers, where necessary) completed the PROM questionnaire on paper and returned it by mail. Mean scores were determined overall and by GD type. Inter-item correlations, content consistency (Cronbach's alpha), and test-retest reliability (Cohen's kappa; main survey only, taken 2 weeks apart) were calculated.Results Sixteen patients (three with GD1; six with GD2; seven with GD3) and 33 patients (nine with GD1; 13 with GD2; 11 with GD3) participated in the pre-test and main survey, respectively. All GD2 patients and one-third (6/18) of GD3 patients required caregivers to complete the questionnaire. Mean scores indicated that the burden was highest in GD2 and lowest in GD1. In the main survey, internal consistency was high (Cronbach's alpha = 0.898 overall, 0.916 for Part 3), and test-retest reliability was high for Part 3 (kappa > 0.60 for 13/16 items) but low for Part 1 (kappa < 0.60 for 12/15 items).Conclusions We have developed a flexible and reliable PROM that can be tailored for use in all types of GD and propose using Parts 1 and 2 for GD1, Parts 2 and 3 for GD2, and Parts 1, 2, and 3 for GD3.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] DEVELOPMENT OF A PATIENT-REPORTED OUTCOME MEASURE FOR CHRONIC HYPOPARATHYROIDISM
    Martin, S. A.
    Chen, K.
    Harris, N., I
    Vera-Llonch, M.
    VALUE IN HEALTH, 2016, 19 (07) : A679 - A679
  • [22] Development and Validation of a Patient-Reported Outcome Measure of Ataxia
    Schmahmann, Jeremy D.
    Pierce, Samantha
    MacMore, Jason
    L'Italien, Gilbert J.
    MOVEMENT DISORDERS, 2021, 36 (10) : 2367 - 2377
  • [23] Development of a Patient-Reported Outcome Measure for Mohs Reconstruction
    Kavanagh, Kaitlin J.
    Christophel, J. Jared
    FACIAL PLASTIC SURGERY & AESTHETIC MEDICINE, 2020, 22 (04) : 274 - 280
  • [24] Development of a Patient-Reported Outcome Measure for Chronic Hypoparathyroidism
    Martin, Susan
    Chen, Kristina
    Harris, Nimanee
    Vera-Llonch, Montserrat
    Krasner, Alan
    ADVANCES IN THERAPY, 2019, 36 (08) : 1999 - 2009
  • [25] Development of a Patient-Reported Outcome Measure for Chronic Hypoparathyroidism
    Susan Martin
    Kristina Chen
    Nimanee Harris
    Montserrat Vera-Llonch
    Alan Krasner
    Advances in Therapy, 2019, 36 : 1999 - 2009
  • [26] Development and pilot testing of a patient-reported outcome measure to assess symptoms of parastomal hernia
    Blazeby, Jane M.
    Murkin, Charlotte
    Rooshenas, Leila
    Elliott, Daisy
    Avery, Kerry
    Chalmers, Katy
    Cousins, Sian
    Pinkney, Thomas
    Blencowe, Natalie
    Reeves, Barnaby C.
    Smart, Neil
    COLORECTAL DISEASE, 2024, 26 (02) : 364 - 370
  • [27] A patient-reported outcome measure in Parkinson's disease
    Mischley, L. K.
    MOVEMENT DISORDERS, 2014, 29 : S178 - S179
  • [28] Development and evaluation of a patient-reported outcome measure for patients with venous leg ulcers
    Ruseckaite, Rasa
    Rutherford, Claudia
    Franks, Peter
    McGuinnes, Rosemary
    Turnour, Louise
    Team, Victoria
    Weller, Carolina
    QUALITY OF LIFE RESEARCH, 2018, 27 : S183 - S183
  • [29] THE COELIAC DISEASE ASSESSMENT QUESTIONNAIRE (CDAQ): DEVELOPMENT OF A PATIENT-REPORTED OUTCOME MEASURE
    Crocker, H.
    Jenkinson, C.
    Churchman, D.
    Peters, M.
    VALUE IN HEALTH, 2016, 19 (07) : A595 - A595
  • [30] Development of a new patient-reported outcome measure for Dupuytren disease: A study protocol
    Eckerdal, David
    Lyren, Per-Erik
    Mceachan, Jane
    Lauritzson, Anna
    Nordenskjold, Jesper
    Atroshi, Isam
    HEALTH INFORMATICS JOURNAL, 2024, 30 (04)